AtriCure (ATRC) Fundamentals 2026 — Revenue Analysis | SniperIQ
AtriCure (ATRC) is a US-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of
3.74 on the NASDAQ. This SniperIQ fundamentals page covers AtriCure's valuation, profitability (net margin -0.8%), revenue ($535M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is AtriCure's market cap?
AtriCure (ATRC) has a market capitalization of approximately
3.74 on the NASDAQ. Market cap moves with the live share price.What is AtriCure's P/E ratio?
AtriCure's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is AtriCure?
AtriCure runs a net profit margin of -0.8%, a gross margin of 75.5%, and an operating margin of -0.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does AtriCure generate?
AtriCure reported revenue of $535M for fiscal year 2025, with net income of -
Does AtriCure pay a dividend?
AtriCure does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is AtriCure financially healthy?
AtriCure carries a debt-to-equity ratio of 0.15x and a current ratio of 4.29x, with a market beta of 1.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is AtriCure a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For AtriCure (ATRC) the key facts are: market cap
Track AtriCure's full fundamentals live
Get AtriCure's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.